Pages that link to "Q39210001"

The following pages link to PDK1 inhibition is a novel therapeutic target in multiple myeloma (Q39210001):

Displaying 45 items.

• Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? (Q26774957) ‎ (← links)
• Targeting MYC Dependence by Metabolic Inhibitors in Cancer (Q33608493) ‎ (← links)
• Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells. (Q33803278) ‎ (← links)
• Lactate dehydrogenase A promotes the invasion and proliferation of pituitary adenoma (Q33875716) ‎ (← links)
• Elucidation of the interaction loci of the human pyruvate dehydrogenase complex E2·E3BP core with pyruvate dehydrogenase kinase 1 and kinase 2 by H/D exchange mass spectrometry and nuclear magnetic resonance (Q34972253) ‎ (← links)
• Investigational cancer drugs targeting cell metabolism in clinical development (Q35615701) ‎ (← links)
• Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors (Q35684292) ‎ (← links)
• Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice (Q36175385) ‎ (← links)
• Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells (Q36208283) ‎ (← links)
• Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation (Q36545216) ‎ (← links)
• PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer (Q36557218) ‎ (← links)
• Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases (Q36743618) ‎ (← links)
• Emerging metabolic targets in the therapy of hematological malignancies (Q37137623) ‎ (← links)
• 3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer. (Q37167731) ‎ (← links)
• CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells (Q37396842) ‎ (← links)
• High-Throughput Screening to Identify Plant Derived Human LDH-A Inhibitors (Q37519163) ‎ (← links)
• MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1. (Q37604355) ‎ (← links)
• Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers (Q37706613) ‎ (← links)
• Immunohistochemical analysis of PDK1 expression in breast cancer (Q37734310) ‎ (← links)
• 2-Methoxyestradiol enhances radiosensitivity in radioresistant melanoma MDA-MB-435R cells by regulating glycolysis via HIF-1α/PDK1 axis (Q38710762) ‎ (← links)
• Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies (Q38731939) ‎ (← links)
• Cancer metabolism: a therapeutic perspective (Q38824435) ‎ (← links)
• High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma (Q38832538) ‎ (← links)
• Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. (Q39004271) ‎ (← links)
• Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells (Q39078376) ‎ (← links)
• The hypoxia signalling pathway in haematological malignancies. (Q39246376) ‎ (← links)
• Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. (Q39896435) ‎ (← links)
• Global view of cognate kinase activation by the human pyruvate dehydrogenase complex (Q41859582) ‎ (← links)
• CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4. (Q42371512) ‎ (← links)
• Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. (Q42977115) ‎ (← links)
• Immunohistochemical analysis of PDK1, PHD3 and HIF-1α expression defines the hypoxic status of neuroblastoma tumors (Q45111014) ‎ (← links)
• Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-Targeting Pyruvate Dehydrogenase Kinase Inhibitors. (Q48353659) ‎ (← links)
• Upregulation of PDK1 associates with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro. (Q51033477) ‎ (← links)
• PDK1-WNK1 signaling is affected by HBx and involved in the viability and metastasis of hepatic cells. (Q52643619) ‎ (← links)
• Metabolic Features of Multiple Myeloma. (Q53694850) ‎ (← links)
• PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism (Q58780167) ‎ (← links)
• The Influence of Metabolism on Drug Response in Cancer (Q59136910) ‎ (← links)
• PDK-1 mediated Hippo-YAP-IRS2 signaling pathway and involved in the apoptosis of non-small cell lung cancer cells (Q64262573) ‎ (← links)
• PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma (Q89346507) ‎ (← links)
• Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma (Q89626384) ‎ (← links)
• UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expres7sion of PDK1 through PI3K/AKT signaling (Q90166746) ‎ (← links)
• Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia (Q91814085) ‎ (← links)
• Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy (Q92637730) ‎ (← links)
• Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma (Q94600244) ‎ (← links)
• Genome instability in multiple myeloma (Q97531377) ‎ (← links)